Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cephalon submits OraVescent NDA

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Cephalon submits an NDA for its effervescent buccal fentanyl product OraVescent. Announced Sept. 6, the application seeks an indication for management of breakthrough pain in patients with cancer who are already receiving or who are tolerant to opioid therapy for underlying persistent pain. "This NDA, submitted on schedule, is the fourth of five new product opportunities that Cephalon is pursuing over a 15-month period," the firm said. Cephalon previously indicated that its goal of achieving four NDA approvals in 2005-2006 could double the firm's size by 2008 (1Pharmaceutical Approvals Monthly May 2005, p. 13). The OraVescent NDA includes one pivotal trial with statistically significant pain improvements and interim analyses from three ongoing Phase III trials in opioid-tolerant patients...

You may also be interested in...



Cephalon Strategy: Four NDAs In 2005-2006 To Double Firm’s Size

Cephalon goal of four NDA submissions in 14 months is on-track, with approvals forecast to double size of company by 2008. Pediatric sales force of 250 to be hired to detail modafinil for ADHD, with debut slated for early 2006. FDA rejects trade name Attenace. OraVescent breakthrough cancer pain NDA slated for Q3 2005; Gabitril sNDA for generalized anxiety in Q1 2006

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.

Topics

UsernamePublicRestriction

Register

OM016204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel